Hikma Pharmaceuticals (GB:HIK) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Hikma Pharmaceuticals PLC has successfully acquired Xellia Pharmaceuticals’ US finished dosage form business, which includes a commercial portfolio, a manufacturing facility, and an R&D center, for $135 million with up to $50 million in additional payments based on milestones. The acquisition aims to bolster Hikma’s US injectables business, enhance its portfolio with advanced manufacturing technologies, and is expected to contribute positively to earnings after the first year. This strategic move is projected to support the company’s growth and long-term benefits in the pharmaceutical industry.
For further insights into GB:HIK stock, check out TipRanks’ Stock Analysis page.
